16773-51-6

Usage

Uses

Used in Pharmaceutical Industry:
2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole is used as an antiprotozoal and antibacterial agent for the treatment of infections caused by anaerobic bacteria and protozoa. Its application is based on its ability to penetrate the cells of microorganisms and damage their DNA, resulting in the destruction of the pathogens.
Used in Treatment of Parasitic Infections:
In the field of parasitology, 2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole is used as a therapeutic agent for a variety of parasitic infections, including giardiasis, trichomoniasis, and amoebiasis. Its effectiveness is attributed to its capacity to disrupt the cellular processes of the parasites, thereby alleviating the symptoms and clearing the infection.
Used in Cancer Research:
2-methyl-4-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole is also used in the research of cancer biology as it has demonstrated potential anti-cancer properties. In laboratory studies, MNZ has shown the ability to inhibit the growth of certain cancer cells, suggesting that it could be a candidate for further investigation and development in oncology.

Upstream product

• 14419-11-5 (±)-1-chloro-3-(2-methyl-4-nitro-1H-imidazol-1-yl)propan-2-ol 

Relevant academic research and scientific papers

2-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study

Trichomoniasis is the most prevalent, non-viral sexually transmitted diseases (STD) caused by amitochondriate protozoan Trichomonas vaginalis. Increased resistance of T.?vaginalis to the marketed drug Metronidazole necessitates the development of newer chemical entities. A library of sixty 2-methyl-4/5-nitroimidazole derivatives was synthesized via nucleophilic ring opening reaction of epoxide and the efficacies against drug-susceptible and -resistant Trichomonas vaginalis were evaluated. All the molecules except two were found to be active against both susceptible and resistant strains with MICs ranging 8.55–336.70?μM and 28.80–1445.08?μM, respectively. Most of the compounds were remarkably more effective than the standard Metronidazole. This study analyzes the in?vitro and in?vivo activities of the new 5-nitroimidazoles, which were found to be safe against human cervical HeLa cells with good selectivity index. The exploration of SAR by the synthesis of four different prototypes and 3D-QSAR study has shown the importance of prototype 1 over other prototypes.

Lipase-catalyzed resolution of both enantiomers of Ornidazole and some analogues

The resolution of the enantiomers of the chemotherapeutic Ornidazole (Tiberal) 1a was achieved by acetylation of the racemic compound with vinylacetate in the presence of lipase Amano PS (from Pseudomonas cepacia). The halogen analogues 4a-6a and the corresponding 4-nitro-derivatives 1b and 4b-6b were also synthesized and the enantiomers were separated by kinetic enzymatic resolution. The absolute configuration of two compounds was determined by X-ray crystallography.